{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T13:13:46Z","timestamp":1770470026890,"version":"3.49.0"},"reference-count":145,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Respiratory Medicine"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1586\/17476348.2014.910457","type":"journal-article","created":{"date-parts":[[2014,5,7]],"date-time":"2014-05-07T08:24:35Z","timestamp":1399451075000},"page":"357-379","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":27,"title":["Recent advances in COPD disease management with fixed-dose long-acting combination therapies"],"prefix":"10.1586","volume":"8","author":[{"given":"Eric D","family":"Bateman","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Pulmonology, University of Cape Town,","place":["South Africa"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald A","family":"Mahler","sequence":"additional","affiliation":[{"name":"Section of Pulmonary and Critical Care Medicine, Geisel School of Medicine at","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claus F","family":"Vogelmeier","sequence":"additional","affiliation":[{"name":"Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-Universit\u00e4t Marburg,","place":["Germany, Member of the German Center for Lung Research (DZL)"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jadwiga A","family":"Wedzicha","sequence":"additional","affiliation":[{"name":"Centre for Respiratory Medicine,","place":["UK"]},{"name":"University College London,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Patalano","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald","family":"Banerji","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2014,5,7]]},"reference":[{"key":"e_1_3_3_5_1","unstructured":"Global initiative for chronic Obstructive Lung Disease (GOLD 2014). Global strategy for the diagnosis management and prevention of chronic obstructive pulmonary disease. 2014. Available from: www.goldcopd.org\/uploads\/users\/files\/GOLD_Report_2014.pdf [Last accessed 22 January 2014]"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2006.08.005"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00048912"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00128008"},{"key":"e_1_3_3_9_1","first-page":"1A","article-title":"Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease \u2212 2008 update \u2212 highlights for primary care","volume":"15","author":"O\u2019Donnell DE","year":"2008","unstructured":"O\u2019Donnell DE, Hernandez P, Kaplan A, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease \u2212 2008 update \u2212 highlights for primary care. Can Respir J 2008;15(Suppl A):1A","journal-title":"Can Respir J"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.126.1.220"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2010.03.003"},{"issue":"5","key":"e_1_3_3_12_1","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1378\/chest.105.5.1411","article-title":"In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone","volume":"105","author":"The COMBIVENT Inhalation Solution Study Group","year":"1994","unstructured":"The COMBIVENT Inhalation Solution Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. Chest 1994;105(5):1411-19","journal-title":"Chest"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1513\/pats.200701-016FM"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.2165\/11208620-000000000-00000"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.04.00116004"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.2147\/copd.s1059"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-7-147"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.127.3.809"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2010.09.006"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-14-49"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa063070"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)12459-2"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.03.00031402"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.03.00027003"},{"issue":"4","key":"e_1_3_3_25_1","first-page":"CD006829","article-title":"Combined corticosteroid and long-acting beta-agonist in one inhaler versus long-acting beta-agonists for chronic obstructive pulmonary disease","volume":"17","author":"Nannini LJ","year":"2007","unstructured":"Nannini LJ, Cates CJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta-agonist in one inhaler versus long-acting beta-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2007;17(4):CD006829","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1159\/000315416"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00193908"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S42366"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1513\/pats.200409-045MS"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2012.07.003"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.120.1.258"},{"issue":"3","key":"e_1_3_3_32_1","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1183\/09031936.00023907","article-title":"Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD","volume":"30","author":"Powrie DJ","year":"2007","unstructured":"Powrie DJ, Wilkinson TM, Donaldson GC, et al. Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD. Eur Respir J 2007;30(3):472-8","journal-title":"Eur Respir J"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2009.02.003"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.4104\/pcrj.2011.00102"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00200212"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2014.01.006"},{"key":"e_1_3_3_37_1","article-title":"Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: BLAZE study","author":"Mahler DA","year":"2013","unstructured":"Mahler DA, Decramer M, D\u2019Urzo A, et al. Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: BLAZE study. Eur Respir J 2013;doi: 10.1183\/09031936.00124013. [Epub ahead of print]","journal-title":"Eur Respir J"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(12)70052-8"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(13)70052-3"},{"issue":"57","key":"e_1_3_3_40_1","first-page":"692s","article-title":"QVA149 provides a rapid onset of action which is sustained throughout treatment in patients with COPD [abstract P3385]","volume":"42","author":"Dahl R","year":"2013","unstructured":"Dahl R, Gallagher N, Green Y, et al. QVA149 provides a rapid onset of action which is sustained throughout treatment in patients with COPD [abstract P3385]. Eur Respir J 2013;42(Suppl 57):692s","journal-title":"Eur Respir J"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S49615"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00040712"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S23816"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2010.11.027"},{"issue":"1","key":"e_1_3_3_45_1","first-page":"A1488","article-title":"Cardio- and cerebro-vascular safety profile Of QVA149 in patients with COPD: a pooled analysis [abstract]","volume":"187","author":"Ferguson G","year":"2013","unstructured":"Ferguson G, Barnes N, Mehta R, et al. Cardio- and cerebro-vascular safety profile Of QVA149 in patients with COPD: a pooled analysis [abstract]. Am J Respir Crit Care Med 2013;187(1):A1488","journal-title":"Am J Respir Crit Care Med"},{"key":"e_1_3_3_46_1","unstructured":"ClinicalTrials.gov Identifier: NCT01574651. Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01574651"},{"key":"e_1_3_3_47_1","unstructured":"ClinicalTrials.gov Identifier: NCT01610037. Available from: http:\/\/clinicaltrials.gov\/show\/NCT01610037"},{"key":"e_1_3_3_48_1","unstructured":"ClinicalTrials.gov Identifier: NCT01782326. Available from: http:\/\/clinicaltrials.gov\/show\/NCT01782326"},{"key":"e_1_3_3_49_1","unstructured":"ClinicalTrials.gov Identifier: NCT01709903. Available from: http:\/\/clinicaltrials.gov\/show\/NCT01709903"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.13-1579"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2013.06.001"},{"key":"e_1_3_3_52_1","unstructured":"Decramer M Anzueto A Kerwin E et al. Efficacy and safety of umeclidinium\/vilanterol compared with umeclidinium or tiotropium in COPD [poster P3640]. Presented at European Respiratory Society Annual Congress; 7-11 September 2013; Barcelona Spain"},{"key":"e_1_3_3_53_1","unstructured":"Anzueto A Decramer M Kaelin T et al. The efficacy and safety of umeclidinium\/vilanterol compared with tiotropium in COPD [poster 42837]. Presented at American Thoracic Society International Conference; 17-22 May 2013; Philadelphia USA"},{"key":"e_1_3_3_54_1","unstructured":"ClinicalTrials.gov Identifier: NCT01716520. Available from: http:\/\/clinicaltrials.gov\/show\/NCT01716520"},{"key":"e_1_3_3_55_1","unstructured":"GlaxoSmithKline Clinical Study Register. Result summary DB2116133. A randomized double-blind 3-way cross-over study to evaluate lung function response after treatment with umeclidinium 62.5 mcg vilanterol 25 mcg and umeclidinium\/vilanterol 62.5\/25 mcg once-daily in subjects with chronic obstructive pulmonary disease (COPD). 2013. Available from: www.gsk-clinicalstudyregister.com\/files2\/a4eb7507-0808-4196-b85d-70c63e287917 [Last accessed 5 December 2013]"},{"key":"e_1_3_3_56_1","unstructured":"Maltais F Singh S Donald A et al. Effects of a combination of vilanterol and umeclidinium on exercise endurance in subjects with COPD: two randomised clinical trials [poster P761]. Presented at European Respiraory Society Annual Congess; 7-11 September 2013; Barcelona Spain"},{"key":"e_1_3_3_57_1","unstructured":"Food and Drug Administration (FDA). FDA Briefing Document. Pulmonary-Allergy Drugs Advisory Committee Meeting. NDA 203-975: umeclidinium and vilanterol inhalation powder for the long-term once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). 2013. Available from: www.fda.gov\/downloads\/advisorycommittees\/committeesmeetingmaterials\/drugs\/pulmonary-allergydrugsadvisorycommittee\/ucm367411.pdf [Last accessed 5 December 2013]"},{"key":"e_1_3_3_58_1","unstructured":"Donohue J Niewoehner D Brooks J et al. Long-term safety and tolerability of umeclidinium\/vilanterol and umeclidinium in COPD [poster P760]. Presented at European Respiratory Society Annual Congress; 7-11 September 2013; Barcelona Spain"},{"key":"e_1_3_3_59_1","unstructured":"ClinicalTrials.gov Identifier: NCT01777334. Available from: http:\/\/clinicaltrials.gov\/show\/NCT01777334"},{"key":"e_1_3_3_60_1","unstructured":"ClinicalTrials.gov Identifier: NCT01899742. Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01899742"},{"key":"e_1_3_3_61_1","unstructured":"ClinicalTrials.gov Identifier: NCT01817764. Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01817764"},{"key":"e_1_3_3_62_1","unstructured":"ClinicalTrials.gov Identifier: NCT01822899. Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01822899"},{"key":"e_1_3_3_63_1","unstructured":"ClinicalTrials.gov Identifier: NCT01879410. Available from: http:\/\/clinicaltrials.gov\/show\/NCT01879410"},{"key":"e_1_3_3_64_1","doi-asserted-by":"crossref","unstructured":"Reisner C St Rose E Strom S et al. Fixed combination of glycopyrrolate and formoterol MDI (GFF-MDI) demonstrates superior inspiratory capacity (IC) compared to tiotropium DPI (Tio) following 7 days dosing in a randomized double-blind placebo-controlled phase 2b study in patients with COPD [poster P879]. Presented at European Respiratory Society Annual Congress; 24-28 September 2011; Amsterdam The Netherlands","DOI":"10.1164\/ajrccm-conference.2011.183.1_MeetingAbstracts.A6435"},{"key":"e_1_3_3_65_1","doi-asserted-by":"crossref","unstructured":"Reisner C Fogarty C Spangenthal S et al. Novel combination of glycopyrrolate and formoterol MDI (GFF-MDI) provides superior bronchodilation compared to its components administered alone tiotropium DPI and formoterol DPI in a randomized double-blind placebo-controlled Phase 2b study in patients with COPD [poster]. Presented at American Thoracic Society International Conference; 13-18 May 2011; Denver Colorado USA","DOI":"10.1164\/ajrccm-conference.2011.183.1_MeetingAbstracts.A6435"},{"issue":"1","key":"e_1_3_3_66_1","first-page":"A6435","article-title":"Novel combination of glycopyrrolate and formoterol Mdi (GFF-MDI) provides superior bronchodilation compared to its components administered alone, tiotropium DPI, and formoterol DPI in a randomized, double-blind, placebo-controlled Phase 2b study in patients with COPD [abstract]","volume":"183","author":"Reisner C","year":"2011","unstructured":"Reisner C, Fogarty C, Spangenthal S, et al. Novel combination of glycopyrrolate and formoterol Mdi (GFF-MDI) provides superior bronchodilation compared to its components administered alone, tiotropium DPI, and formoterol DPI in a randomized, double-blind, placebo-controlled Phase 2b study in patients with COPD [abstract]. Am J Respir Crit Care Med 2011;183(1):A6435","journal-title":"Am J Respir Crit Care Med"},{"key":"e_1_3_3_67_1","doi-asserted-by":"crossref","unstructured":"Reisner C Rennard SI Fogarty C et al. Pearl Therapeutics\u2019 combination LAMA\/LABA MDI (GFF-MDI PT003) provides a significant benefit on home peak expiratory flow rate (PEFR) and reduces the need for rescue albuterol use compared to its components administered alone Spiriva\u00ae Handihaler\u00ae and Foradil\u00ae Aerolizer\u00ae in a randomized double-blind placebo-controlled Phase 2b study in patients with COPD [poster]. Presented at American Thoracic Society International Conference; 18-23 May 2012; San Francisco California USA","DOI":"10.1164\/ajrccm-conference.2012.185.1_MeetingAbstracts.A2259"},{"key":"e_1_3_3_68_1","doi-asserted-by":"crossref","unstructured":"Reisner C Fernandez C Orevillo C et al. Pearl Therapeutics\u2019 combination LAMA\/LABA MDI (GFF MDI PT003) provides comparable metabolic and ECG safety to Spiriva\u00ae HandiHaler\u00ae and placebo in patients with COPD [poster]. Presented at American Thoracic Society International Conference; 18-23 May 2012; San Francisco California USA","DOI":"10.1164\/ajrccm-conference.2012.185.1_MeetingAbstracts.A2925"},{"key":"e_1_3_3_69_1","unstructured":"ClinicalTrials.gov Identifier: NCT01854645. Available from: http:\/\/clinicaltrials.gov\/show\/NCT01854645"},{"key":"e_1_3_3_70_1","unstructured":"ClinicalTrials.gov Identifier: NCT01854658. Available from: http:\/\/clinicaltrials.gov\/show\/NCT01854658"},{"key":"e_1_3_3_71_1","unstructured":"ClinicalTrials.gov Identifier: NCT01970878. Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01970878"},{"issue":"54","key":"e_1_3_3_72_1","first-page":"1014s","article-title":"Four weeks once daily treatment with tiotropium+olodaterol (BI 1744) fixed dose combination compared with tiotropium in COPD patients [abstract 5557]","volume":"36","author":"Maltais F","year":"2010","unstructured":"Maltais F, Beck E, Webster D, et al. Four weeks once daily treatment with tiotropium+olodaterol (BI 1744) fixed dose combination compared with tiotropium in COPD patients [abstract 5557]. Eur Respir J 2010;36(Suppl 54):1014s","journal-title":"Eur Respir J"},{"key":"e_1_3_3_73_1","unstructured":"Aalbers R Maleki-Yazdi MR Hamilton A et al. Dose-finding study for tiotropium and olodaterol when administered in combination via the Respimat\u00ae inhaler in patients with COPD [Poster P2882]. Presented at European Respiratory Society Annual Congress; 1-5 September 2012; Vienna Austria"},{"key":"e_1_3_3_74_1","unstructured":"ClinicalTrials.gov Identifier: NCT01431274. Available from: http:\/\/clinicaltrials.gov\/show\/NCT01431274"},{"key":"e_1_3_3_75_1","unstructured":"ClinicalTrials.gov Identifier: NCT01431287. Available from: http:\/\/clinicaltrials.gov\/show\/NCT01431287"},{"key":"e_1_3_3_76_1","unstructured":"ClinicalTrials.gov Identifier: NCT01969721. Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01969721"},{"key":"e_1_3_3_77_1","unstructured":"ClinicalTrials.gov Identifier: NCT01533935. Available from: http:\/\/clinicaltrials.gov\/show\/NCT01533935"},{"key":"e_1_3_3_78_1","unstructured":"ClinicalTrials.gov Identifier: NCT01533922. Available from: http:\/\/clinicaltrials.gov\/show\/NCT01533922"},{"key":"e_1_3_3_79_1","unstructured":"ClinicalTrials.gov Identifier: NCT01525615. Available from: http:\/\/clinicaltrials.gov\/show\/NCT01525615"},{"issue":"4","key":"e_1_3_3_80_1","doi-asserted-by":"crossref","first-page":"A136","DOI":"10.1136\/thx.2010.150987.38","article-title":"Efficacy and safety of once-daily aclidinium bromide 200 \u00b5g in combination with formoterol in patients with COPD [abstract P137]","volume":"65","author":"\u015aliwi\u0144ski P","year":"2010","unstructured":"\u015aliwi\u0144ski P, Perng D-W, Chuchalin A, Jones PW. Efficacy and safety of once-daily aclidinium bromide 200 \u00b5g in combination with formoterol in patients with COPD [abstract P137]. Thorax 2010;65(Suppl 4):A136","journal-title":"Thorax"},{"key":"e_1_3_3_81_1","unstructured":"ClinicalTrials.gov Identifier: NCT01437397. Available from: http:\/\/clinicaltrials.gov\/show\/NCT01437397"},{"key":"e_1_3_3_82_1","unstructured":"Almirall. Press Release: Almirall and Forest Laboratories announce positive results of a Phase III Study for aclidinium and formoterol combination in COPD. 2013.Available from: www.almirall.com\/webcorp2\/cda\/comunicacion_detalle_noticia.jsp?id=2500 [Last accessed 10 January 2014]"},{"key":"e_1_3_3_83_1","unstructured":"ClinicalTrials.gov Identifier: NCT01572792. Available from: http:\/\/clinicaltrials.gov\/show\/NCT01572792"},{"key":"e_1_3_3_84_1","unstructured":"ClinicalTrials.gov Identifier: NCT01908140. Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01908140"},{"key":"e_1_3_3_85_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.02.00283202"},{"key":"e_1_3_3_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2012.12.014"},{"key":"e_1_3_3_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2012.12.016"},{"key":"e_1_3_3_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(13)70040-7"},{"key":"e_1_3_3_89_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00054213"},{"key":"e_1_3_3_90_1","unstructured":"ClinicalTrials.gov Identifier: NCT01627327. Available from: http:\/\/clinicaltrials.gov\/show\/NCT01627327"},{"key":"e_1_3_3_91_1","unstructured":"GlaxoSmithKline Clinical Study Register. Result summary HZC115805. A 12-week study to evaluate the 24-hour pulmonary function profile of fluticasone furoate\/vilanterol (FF\/VI) inhalation powder 100\/25mcg once-daily via a novel dry powder inhaler compared with tiotropium bromide inhalation powder 18mcg delivered once-daily via the HandiHaler in subjects with chronic obstructive pulmonary disease (COPD) who have or are at risk for co-morbid cardiovascular disease. Available from: www.gsk-clinicalstudyregister.com\/study\/115805?study_ids=115805#rs [Last accessed 14 January 2014]"},{"key":"e_1_3_3_92_1","unstructured":"ClinicalTrials.gov Identifier: NCT01551758. Available from: http:\/\/clinicaltrials.gov\/show\/NCT01551758"},{"issue":"5","key":"e_1_3_3_93_1","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1183\/09031936.00087312","article-title":"The study to understand mortality and morbidity in COPD (SUMMIT) study protocol","volume":"41","author":"Vestbo J","year":"2013","unstructured":"Vestbo J, Anderson J, Brook RD, et al. The study to understand mortality and morbidity in COPD (SUMMIT) study protocol. Eur Respir J 2013;41(5):1017-22","journal-title":"Eur Respir J"},{"key":"e_1_3_3_94_1","unstructured":"ClinicalTrials.gov Identifier: NCT01313676. Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01313676"},{"key":"e_1_3_3_95_1","unstructured":"ClinicalTrials.gov Identifier: NCT01706328. Available from: http:\/\/clinicaltrials.gov\/show\/NCT01706328"},{"key":"e_1_3_3_96_1","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S29444"},{"key":"e_1_3_3_97_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2010.09.008"},{"key":"e_1_3_3_98_1","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S23746"},{"issue":"57","key":"e_1_3_3_99_1","first-page":"141s","article-title":"FORWARD: a study of extrafine beclomethasone\/formoterol compared with formoterol alone in patients with severe COPD and a history of exacerbations [abstract P762]","volume":"42","author":"Agusti A","year":"2013","unstructured":"Agusti A, Corradi M, Cohuet G, et al. FORWARD: a study of extrafine beclomethasone\/formoterol compared with formoterol alone in patients with severe COPD and a history of exacerbations [abstract P762]. Eur Respir J 2013;42(Suppl 57):141s","journal-title":"Eur Respir J"},{"key":"e_1_3_3_100_1","unstructured":"ClinicalTrials.gov Identifier: NCT00929851. Available from: http:\/\/clinicaltrials.gov\/show\/NCT00929851"},{"key":"e_1_3_3_101_1","unstructured":"ClinicalTrials.gov Identifier: NCT01245569. Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01245569"},{"key":"e_1_3_3_102_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2011.594123"},{"key":"e_1_3_3_103_1","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S18529"},{"key":"e_1_3_3_104_1","doi-asserted-by":"publisher","DOI":"10.3109\/21556660.2013.766197"},{"key":"e_1_3_3_105_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2010.518916"},{"key":"e_1_3_3_106_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2466-13-72"},{"key":"e_1_3_3_107_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2011.02832.x"},{"key":"e_1_3_3_108_1","doi-asserted-by":"publisher","DOI":"10.2147\/copd.2006.1.3.251"},{"key":"e_1_3_3_109_1","doi-asserted-by":"publisher","DOI":"10.1183\/09059180.05.00009605"},{"key":"e_1_3_3_110_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.03.00068503a"},{"key":"e_1_3_3_111_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201310-1863PP"},{"key":"e_1_3_3_112_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00098307"},{"key":"e_1_3_3_113_1","unstructured":"Global initiative for chronic Obstructive Lung Disease (GOLD 2007). Global strategy for the diagnosis management and prevention of chronic obstructive pulmonary disease. 2007. Available from: www.goldcopd.org\/Guidelines\/guidelines-global-strategy-for-diagnosis-management-2007.html [Last accessed 10 January 2014]"},{"key":"e_1_3_3_114_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2012.03.008"},{"key":"e_1_3_3_115_1","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2012-202678.246"},{"key":"e_1_3_3_116_1","doi-asserted-by":"publisher","DOI":"10.4414\/smw.2010.13053"},{"key":"e_1_3_3_117_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-8-200704170-00152"},{"key":"e_1_3_3_118_1","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2007.087213"},{"key":"e_1_3_3_119_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200904-0492OC"},{"key":"e_1_3_3_120_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2009.10.005"},{"key":"e_1_3_3_121_1","doi-asserted-by":"crossref","unstructured":"Karner C Cates CJ. Combination inhaled steroid and long-acting beta(2)-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2011; CD008532","DOI":"10.1002\/14651858.CD008532.pub2"},{"key":"e_1_3_3_122_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2013.03.015"},{"key":"e_1_3_3_123_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00165712"},{"issue":"1","key":"e_1_3_3_124_1","first-page":"A1608","article-title":"The in-vitro pharmacology of PF-4348235 at native receptors - a novel inhaled dual antimuscarinic\/beta2 adrenoceptor agonist [abstract]","volume":"183","author":"Patel S","year":"2011","unstructured":"Patel S, Marshall S, Summerhill S, et al. The in-vitro pharmacology of PF-4348235 at native receptors - a novel inhaled dual antimuscarinic\/beta2 adrenoceptor agonist [abstract]. Am J Respir Crit Care Med 2011;183(1):A1608","journal-title":"Am J Respir Crit Care Med"},{"issue":"54","key":"e_1_3_3_125_1","first-page":"218s","article-title":"Demonstration of dual pharmacology in vivo of PF-3429281: a novel inhaled dual antimuscarinic\/beta2 agonist [abstract P1231]","volume":"36","author":"Philip J","year":"2010","unstructured":"Philip J, Gray A, Clarke N, et al. Demonstration of dual pharmacology in vivo of PF-3429281: a novel inhaled dual antimuscarinic\/beta2 agonist [abstract P1231]. Eur Respir J 2010;36(Suppl 54):218s","journal-title":"Eur Respir J"},{"key":"e_1_3_3_126_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.110.069120"},{"key":"e_1_3_3_127_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200906-0876OC"},{"key":"e_1_3_3_128_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.09-0011"},{"key":"e_1_3_3_129_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12-2332"},{"key":"e_1_3_3_130_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.04.039"},{"key":"e_1_3_3_131_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2010.112"},{"key":"e_1_3_3_132_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00106406"},{"key":"e_1_3_3_133_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0805800"},{"key":"e_1_3_3_134_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200912-1843CC"},{"key":"e_1_3_3_135_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909883"},{"key":"e_1_3_3_136_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0037483"},{"key":"e_1_3_3_137_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105482"},{"key":"e_1_3_3_138_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201106-0992OC"},{"key":"e_1_3_3_139_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00213711"},{"issue":"4","key":"e_1_3_3_140_1","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2217\/cpr.13.38","article-title":"Optimizing the management of chronic obstructive pulmonary disease: applying the GOLD strategy","volume":"10","author":"D\u2019Urzo A","year":"2013","unstructured":"D\u2019Urzo A. Optimizing the management of chronic obstructive pulmonary disease: applying the GOLD strategy. Clin Pract 2013;10(4):481-92","journal-title":"Clin Pract"},{"key":"e_1_3_3_141_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0194-8"},{"issue":"57","key":"e_1_3_3_142_1","first-page":"750s","article-title":"Once-daily QVA149 improves symptom scores in patients with COPD [abstract P3637]","volume":"42","author":"Welte T","year":"2013","unstructured":"Welte T, Dahl R, Chen H, et al. Once-daily QVA149 improves symptom scores in patients with COPD [abstract P3637]. Eur Respir J 2013;42(Suppl 57):750s","journal-title":"Eur Respir J"},{"issue":"57","key":"e_1_3_3_143_1","first-page":"693s","article-title":"Dual bronchodilation with once-daily QVA149 improves dyspnea and health status and reduces symptoms and rescue medication use in patients with COPD: the IGNITE trials [abstract P3388]","volume":"42","author":"Banerji D","year":"2013","unstructured":"Banerji D, Alagappan V, Green Y, et al. Dual bronchodilation with once-daily QVA149 improves dyspnea and health status and reduces symptoms and rescue medication use in patients with COPD: the IGNITE trials [abstract P3388]. Eur Respir J 2013;42(Suppl 57):693s","journal-title":"Eur Respir J"},{"issue":"57","key":"e_1_3_3_144_1","first-page":"749s","article-title":"QVA149 provides superior peak lung function in patients with COPD [abstract P3634]","volume":"42","author":"Barnes N","year":"2013","unstructured":"Barnes N, Hashimoto S, Nagase T, et al. QVA149 provides superior peak lung function in patients with COPD [abstract P3634]. Eur Respir J 2013;42(Suppl 57):749s","journal-title":"Eur Respir J"},{"issue":"1","key":"e_1_3_3_145_1","first-page":"A4271","article-title":"Dual bronchodilation with once-daily QVA149 significantly improves lung function versus single bronchodilators and salmeterol\/fluticasone [abstract]","volume":"187","author":"Bateman ED","year":"2013","unstructured":"Bateman ED, Ferguson GT, Welte T, et al. Dual bronchodilation with once-daily QVA149 significantly improves lung function versus single bronchodilators and salmeterol\/fluticasone [abstract]. Am J Respir Crit Care Med 2013;187(1):A4271","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"e_1_3_3_146_1","first-page":"A4272","article-title":"Dual bronchodilation with once-daily QVA149 provides significantly improved clinical outcomes versus mono-bronchodilator therapy: the SHINE study [abstract]","volume":"187","author":"Welte T","year":"2013","unstructured":"Welte T, Gallagher N, Green Y, et al. Dual bronchodilation with once-daily QVA149 provides significantly improved clinical outcomes versus mono-bronchodilator therapy: the SHINE study [abstract]. Am J Respir Crit Care Med 2013;187(1):A4272","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"e_1_3_3_147_1","first-page":"A184","article-title":"Comparison of COPD exacerbations with once-daily QVA149 versus twice-daily salmeterol\/fluticasone combination: the ILLUMINATE study [abstract P237]","volume":"68","author":"Vogelmeier C","year":"2013","unstructured":"Vogelmeier C, Bateman ED, Chen H, Banerji D. Comparison of COPD exacerbations with once-daily QVA149 versus twice-daily salmeterol\/fluticasone combination: the ILLUMINATE study [abstract P237]. Thorax 2013;68(Suppl 3):A184-5","journal-title":"Thorax"},{"key":"e_1_3_3_148_1","unstructured":"GlaxoSmithKline. FDA Advisory Committee Briefing Document. ANORO\u2122 ELLIPTA\u2122 (umeclidinium bromide\/vilanterol inhalation powder) for treatment of chronic obstructive pulmonary disease. NDA 203975. Presented to Pulmonary-Allergy Drug Advisory Committee. 2013. Available from: www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/Pulmonary-AllergyDrugsAdvisoryCommittee\/UCM367414.pdf [Last accessed 5 December 2013]"},{"key":"e_1_3_3_149_1","unstructured":"GlaxoSmithKline Clinical Study Register. Result summary DB2116844. Results report for a meta-analysis of DB2113360 and DB2113374: an integrated review of transitional dyspnoea index data for umeclidinium\/vilanterol umeclidinium vilanterol and tiotropium over 24 weeks in subjects with COPD. 2013. Available from: www.gsk-clinicalstudyregister.com\/files2\/1f37e00a-6090-4648-9a79-4e49e481af40 [Last accessed 5 December 2013]"}],"container-title":["Expert Review of Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1586\/17476348.2014.910457","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T18:50:39Z","timestamp":1770403839000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1586\/17476348.2014.910457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,7]]},"references-count":145,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["10.1586\/17476348.2014.910457"],"URL":"https:\/\/doi.org\/10.1586\/17476348.2014.910457","relation":{},"ISSN":["1747-6348","1747-6356"],"issn-type":[{"value":"1747-6348","type":"print"},{"value":"1747-6356","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,7]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierx20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierx20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2014-05-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}